Has Cathleen Mullarkey Desapio, MD received payments from drug or device companies?

Yes. Drug and device makers reported $182,512 in general payments to Cathleen Mullarkey Desapio, MD across 730 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Cathleen Mullarkey Desapio, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Cathleen Mullarkey Desapio, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Cathleen Mullarkey Desapio, MD

Endocrinology, Diabetes & Metabolism · Princeton, NJNPI 1225073505

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $139,205 of the $182,512 with a category attached, or 76.3%. 32 manufacturers reported payments, led by AstraZeneca at 37.3% of the total. Reporting peaked in 2019 at $99,189 and has fallen 99.3% since, to $654 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$182,512in general payments, 2019–2025

Across 730 payments — averaging $250.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$68K
Mannkind Corporation$38K
Amarin Pharma, Inc.$16K
Johnson & Johnson$16K
AbbVie$15K
Boehringer Ingelheim$14K
plus $17K from 26 others

What the payments were for

Consulting fees$9,6455%
Speaking & faculty fees$139,20576%
Travel & lodging$16,8879%
Food & beverage$16,7049%
Education$710%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	196	$68,167
Mannkind Corporation	87	$37,521
Amarin Pharma, Inc.	63	$16,152
Johnson & Johnson	60	$15,910
AbbVie	45	$14,506
Boehringer Ingelheim	35	$13,733
Lilly USA, LLC	29	$6,832
Medtronic(2 entities)	27	$2,599
Corcept Therapeutics	13	$2,325
Abbott	15	$962
Novo Nordisk	25	$939
Amneal Pharmaceuticals LLC	31	$539
Sanofi-aventis U.S. LLC	25	$351
Amgen(2 entities)	15	$240
Dexcom, Inc.	2	$187
BETA Bionics, Inc.	2	$167
Insulet Corporation	2	$166
Bayer	2	$144
Kowa Pharmaceuticals America, Inc.	10	$138
Shire North American Group Inc	6	$138
Endo Pharmaceuticals Inc.	9	$115
Tandem Diabetes Care, Inc.	2	$104
Radius Health, Inc.	4	$98
Janssen Scientific Affairs, LLC	3	$87
Merck	6	$82
Esperion Therapeutics, Inc.	3	$77
Intuity Medical Inc	1	$69
IBSA Pharma Inc.	5	$64
Lifescan, Inc.	2	$31
Companion Medical, Inc.	2	$28
Antares Pharma, Inc.	2	$28
Xeris Pharmaceuticals, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FARXIGA$57,317
AFREZZA$36,664
JARDIANCE$19,526
Vascepa$15,211
INVOKANA$14,888
Synthroid$13,972
BYDUREON$7,305
Korlym$2,164
Minimed 670G System$1,778
FREESTYLE LIBRE 3$748
iLet Bionic Pancreas$420
Ozempic$370
DEXCOM G6 TRANSMITTER$175
MINIMED 780G$155
Omnipod$150
iLet Insulin Infusion Kit Inset$140
iLet Insulin Infusion Kit Contact Detach$140
XIGDUO$129
Levemir$125
NovoLog$125

How this compares

$182,512 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024

$29,417

Medicare patients

Services billed

300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Princeton

Alan MosesPrinceton$17K
Angela InzerilloPrinceton$12K
Barry GertzRahway$903K
Nawras MakhsidaRandolph$882K
Marc SandbergFlemington$567K
Joanne WaldstreicherNew Brunswick$441K
Gregory BaroneCherry Hill$433K
Navtika DesaiHillsborough$408K
Taher ModarressiPennington$402K
Atara SchultzTeaneck$357K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →